Japanese nod to PNP drug TarligeMarch 7, 2019
Tarlige tablets has been granted marketing approval in Japan for the treatment of peripheral neuropathic pain (PNP).
This drug, an a2d ligand created by Daiichi Sankyo, was submitted for marketing approval in February 2018 on the basis of the results of a phase 3 clinical trial in patients with diabetic peripheral neuropathic pain (DPNP) and a phase 3 clinical trial in patients with postherpetic neuralgia (PHN). Both trials were conducted in Asia and including Japan.
a2d (Alpha 2 delta) ligand binds to the a2d subunits of voltage-dependent calcium channels DPNP leads to numbness to the extremities and is one of the most common long-term 3 major complications of diabetes.